You are here

Optimization and Lead Selection of Novel Antimycobacterial Agents

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2R44GM110848-02
Agency Tracking Number: R44GM110848
Amount: $1,477,487.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: 300
Solicitation Number: PA14-071
Solicitation Year: 2015
Award Year: 2015
Award Start Date (Proposal Award Date): 2015-09-15
Award End Date (Contract End Date): 2017-08-31
Small Business Information
Boulder, CO 80301-3275
United States
DUNS: 015881952
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (303) 718-3993
Business Contact
Phone: (720) 289-8601
Research Institution

DESCRIPTION provided by applicant The nontuberculous Mycobacteria NTM are a growing public health concern as the number of opportunistic infections increases Although not a reportable disease there is growing epidemiologic evidence to suggest that NTM cause more infections today in the United States than Mycobacterium tuberculosis Mtb yet unlike Mtb there are few dedicated antimicrobial drug discovery programs specifically for NTM Pulmonary disease caused by NTM is especially problematic in patients with underlying susceptibilities such as immunosuppressive medications cystic fibrosis and other lung diseases HIV and malignancies Given the emergence of NTM as a public health issue finding new antibacterial agents is of high importance We have screened libraries of novel compounds for anti NTM activity focusing on M abscessus Mab and identifying several promising small molecule screening hits with chemically tractable scaffolds Our Phase I SBIR grant focused on initial medicinal chemistry optimization of early drug leads that exhibited minimal cytotoxicity high metabolic stability and low potential for resistance development We achieved minimum inhibitory concentration MIC values ranging from to g mL for rapidly growing Mycobacteria RGM including Mab M chelonae M fortiutum and M peregrinum Importantly these compounds also have activity against Mtb MIC to g mL and against permeabilized Gram negative bacteria GNB potentially enabling us to attain broad spectrum antibacterial activity We propose to continue development of a very promising benzothiazole cyclohexylcarboxamide series with Phase II SBIR support focusing on advanced medicinal chemistry lead optimization with a goal of obtaining a strong drug candidate with demonstrated in vivo activity In Aim we will synthesize over a hundred analogs which will be characterized in Aim using a cascade of screening assays beginning with MIC testing against RGM followed by analysis of efflux serum binding hemolysis cytotoxicity metabolic stability frequency of resistance emergence and microbiological spectrum including Mtb and GNB Promising analogs will be screening for murine pharmacokinetic characteristics using an abbreviated pharmacokinetic protocol The goal of Aims and will be to identify multiple lead compounds suitable for in vivo efficacy and toxicity testing during Aim Aim will establish mode of action based on preliminary data indicating that the compounds target MmpL an essential protein thought to be involved in translocation of mycolic acids to or across the periplasmic space Defining the mechanism will facilitate biochemical potency studies thereby supporting the medicinal chemistry effort in Aim In Aim we will scale up synthesis of several lead compounds begin to develop process chemistry strategies to improve synthetic efficiency and evaluate chemical stability We will utilized NIH preclinical services for the evaluation of maximum tolerated dose as well as efficacy in acute and chronic murine models of Mycobacterial infection Successful completion of Aim would bring this exciting chemical series to advanced preclinical development setting the stage for identification of a candidate compound for clinical development We believe this program holds great promise for development of a novel therapeutic agent with broad anti mycobacterial activity PUBLIC HEALTH RELEVANCE Mycobacterial pathogens are intrinsically resistant to most antibiotics and pose an enormous human health challenge While Mycobacterium tuberculosis has been the subject of extensive drug discovery efforts the nontuberculous mycobacteria NTM pose a unique therapeutic challenge in the US Current treatment options for NTM are severely limited prompting this proposal for development of broad spectrum anti mycobacterial agents

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government